|
US3882246A
(en)
|
1971-05-21 |
1975-05-06 |
Merck & Co Inc |
Treatment of skeletal muscle disorders with cyclobenzaprine
|
|
US4968507A
(en)
|
1984-06-20 |
1990-11-06 |
Merck & Co., Inc. |
Controlled porosity osmotic pump
|
|
US5073543A
(en)
|
1988-07-21 |
1991-12-17 |
G. D. Searle & Co. |
Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
|
|
FR2635461B1
(fr)
|
1988-08-18 |
1992-01-17 |
Adir |
Utilisation de derives tricycliques pour l'obtention de medicaments destines au traitement du stress
|
|
US5120548A
(en)
|
1989-11-07 |
1992-06-09 |
Merck & Co., Inc. |
Swelling modulated polymeric drug delivery device
|
|
US5733566A
(en)
|
1990-05-15 |
1998-03-31 |
Alkermes Controlled Therapeutics Inc. Ii |
Controlled release of antiparasitic agents in animals
|
|
US5580578A
(en)
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
|
SG47101A1
(en)
|
1992-07-31 |
1998-03-20 |
Us Bioscience |
Crystalline amifostine compositions and methods for the preparation and use of same
|
|
US5591767A
(en)
|
1993-01-25 |
1997-01-07 |
Pharmetrix Corporation |
Liquid reservoir transdermal patch for the administration of ketorolac
|
|
US6749868B1
(en)
|
1993-02-22 |
2004-06-15 |
American Bioscience, Inc. |
Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
|
|
US5439686A
(en)
|
1993-02-22 |
1995-08-08 |
Vivorx Pharmaceuticals, Inc. |
Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
|
|
US6096331A
(en)
|
1993-02-22 |
2000-08-01 |
Vivorx Pharmaceuticals, Inc. |
Methods and compositions useful for administration of chemotherapeutic agents
|
|
US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
|
JP3746293B2
(ja)
|
1993-02-22 |
2006-02-15 |
アメリカン バイオサイエンス、インコーポレイテッド |
生物製剤のインビボ送達の方法とそのための組成物
|
|
US6753006B1
(en)
|
1993-02-22 |
2004-06-22 |
American Bioscience, Inc. |
Paclitaxel-containing formulations
|
|
US5354566A
(en)
|
1993-06-02 |
1994-10-11 |
Kraft General Foods, Inc. |
Preparation of yeast-leavened dough crusts
|
|
IT1270594B
(it)
|
1994-07-07 |
1997-05-07 |
Recordati Chem Pharm |
Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
|
|
US5834025A
(en)
|
1995-09-29 |
1998-11-10 |
Nanosystems L.L.C. |
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
|
|
US6649186B1
(en)
|
1996-09-20 |
2003-11-18 |
Ethypharm |
Effervescent granules and methods for their preparation
|
|
US20030077227A1
(en)
|
1997-10-01 |
2003-04-24 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
|
|
WO1999018937A1
(en)
|
1997-10-16 |
1999-04-22 |
Merck & Co., Inc. |
New cyclobenzaprine composition
|
|
JP2002514592A
(ja)
|
1998-05-14 |
2002-05-21 |
アルザ コーポレイション |
抗うつ剤療法
|
|
US6761903B2
(en)
|
1999-06-30 |
2004-07-13 |
Lipocine, Inc. |
Clear oil-containing pharmaceutical compositions containing a therapeutic agent
|
|
US7374779B2
(en)
|
1999-02-26 |
2008-05-20 |
Lipocine, Inc. |
Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
|
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
|
US6267985B1
(en)
|
1999-06-30 |
2001-07-31 |
Lipocine Inc. |
Clear oil-containing pharmaceutical compositions
|
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
|
WO2001012174A1
(en)
|
1999-08-13 |
2001-02-22 |
Vela Pharmaceuticals Inc. |
Cyclobenzaprine for treating generalized anxiety disorder and compositions thereof
|
|
US6395788B1
(en)
|
1999-08-13 |
2002-05-28 |
Vela Pharmaceuticals, Inc. |
Methods and compositions for treating or preventing sleep disturbances and associated illnesses using very low doses of cyclobenzaprine
|
|
US6720001B2
(en)
|
1999-10-18 |
2004-04-13 |
Lipocine, Inc. |
Emulsion compositions for polyfunctional active ingredients
|
|
WO2001089476A1
(en)
|
2000-05-19 |
2001-11-29 |
Npd Llc |
Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements
|
|
EP1441708B1
(en)
|
2001-11-05 |
2009-04-08 |
Krele Pharmaceuticals LLC |
Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
|
|
US7659253B2
(en)
|
2002-02-22 |
2010-02-09 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
|
US7105486B2
(en)
|
2002-02-22 |
2006-09-12 |
New River Pharmaceuticals Inc. |
Abuse-resistant amphetamine compounds
|
|
US7700561B2
(en)
|
2002-02-22 |
2010-04-20 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
|
EP1578719A4
(en)
|
2002-10-25 |
2006-07-05 |
Collegium Pharmaceutical Inc |
P-HYDROXY-MILNACIPRAN STEREOISOMERS AND METHODS OF USING THE SAME
|
|
DK1585548T3
(en)
|
2002-12-09 |
2018-09-03 |
Abraxis Bioscience Llc |
COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
|
|
US8688385B2
(en)
|
2003-02-20 |
2014-04-01 |
Mayo Foundation For Medical Education And Research |
Methods for selecting initial doses of psychotropic medications based on a CYP2D6 genotype
|
|
US20050059656A1
(en)
|
2003-04-07 |
2005-03-17 |
Cornell Research Foundation, Inc. |
Compositions and methods for protecting against mitochondria component-mediated pathology
|
|
PT1644019E
(pt)
|
2003-05-29 |
2012-05-23 |
Shire Llc |
Compostos de anfetamina resistentes ao abuso
|
|
EP1685115A1
(en)
|
2003-11-03 |
2006-08-02 |
Warner-Lambert Company LLC |
Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
|
|
US20050143350A1
(en)
|
2003-11-19 |
2005-06-30 |
Seed John C. |
Combination drug therapy to treat obesity
|
|
CA2548281C
(en)
|
2003-12-09 |
2013-11-12 |
Medcrystalforms, Llc |
Method of preparation of mixed phase co-crystals with active agents
|
|
JP5179757B2
(ja)
|
2004-02-17 |
2013-04-10 |
トランセプト ファーマシューティカルズ， インコーポレイティド |
口腔粘膜を介して催眠剤をデリバリーするための組成物及びその使用方法
|
|
TW200531680A
(en)
|
2004-03-03 |
2005-10-01 |
Merz Pharma Gmbh & Co Kgaa |
Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
|
|
US8216610B2
(en)
|
2004-05-28 |
2012-07-10 |
Imaginot Pty Ltd. |
Oral paracetamol formulations
|
|
US20070196364A1
(en)
|
2004-07-27 |
2007-08-23 |
Human Genome Sciences, Inc. |
Pharmaceutical Formulation and Process
|
|
US7532935B2
(en)
|
2005-07-29 |
2009-05-12 |
Cyberonics, Inc. |
Selective neurostimulation for treating mood disorders
|
|
US7994220B2
(en)
*
|
2005-09-28 |
2011-08-09 |
Cypress Bioscience, Inc. |
Milnacipran for the long-term treatment of fibromyalgia syndrome
|
|
US20090069267A1
(en)
|
2006-01-17 |
2009-03-12 |
Abrams Daniel J |
Central administration of stable formulations of therapeutic agents for cns conditions
|
|
US20080146672A1
(en)
|
2006-12-08 |
2008-06-19 |
Denton Marcia Marye |
Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue
|
|
WO2008137923A2
(en)
|
2007-05-07 |
2008-11-13 |
Chelsea Therapeutics, Inc. |
Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
|
|
EP2170064A4
(en)
|
2007-06-22 |
2010-08-04 |
Merck Sharp & Dohme |
6,5-pyrrolopiperidine tachykinin receptor antagonists
|
|
CN101951912A
(zh)
|
2007-07-23 |
2011-01-19 |
辛诺西亚治疗公司 |
创伤后应激障碍的治疗
|
|
US20090060983A1
(en)
|
2007-08-30 |
2009-03-05 |
Bunick Frank J |
Method And Composition For Making An Orally Disintegrating Dosage Form
|
|
EP2601935A1
(en)
|
2007-09-25 |
2013-06-12 |
Solubest Ltd. |
Compositions comprising lipophilic active compounds and method for their preparation
|
|
US20100247649A1
(en)
|
2007-10-30 |
2010-09-30 |
Dr. Reddy's Laboratories Ltd. |
Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
|
|
US20090148532A1
(en)
|
2007-12-06 |
2009-06-11 |
Venkatesh Gopi M |
Preparation of controlled release skeletal muscle relaxant dosage forms
|
|
CA2905541C
(en)
|
2008-01-09 |
2020-02-11 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
|
|
WO2009100222A1
(en)
|
2008-02-08 |
2009-08-13 |
Qps Llc |
Non-polymeric compositions for controlled drug delivery
|
|
US9314469B2
(en)
|
2008-05-05 |
2016-04-19 |
Tonix Pharma Holdings Limited |
Method for treating neurocognitive dysfunction
|
|
JP5380909B2
(ja)
|
2008-05-30 |
2014-01-08 |
株式会社ブリヂストン |
金型及び樹脂発泡成形品の成形方法
|
|
US20100266682A1
(en)
|
2008-12-10 |
2010-10-21 |
Nipun Davar |
Polyethylene glycol-coated sodium carbonate as a pharmaceutical excipient and compositions produced from the same
|
|
EP2233134A1
(en)
|
2009-03-27 |
2010-09-29 |
McNeil AB |
Multi-portion intra-oral dosage form with organoleptic properties
|
|
US20100247586A1
(en)
|
2009-03-27 |
2010-09-30 |
Andreas Hugerth |
Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
|
|
US8807979B2
(en)
|
2009-09-24 |
2014-08-19 |
Mcneil-Ppc, Inc. |
Machine for the manufacture of dosage forms utilizing radiofrequency energy
|
|
EP2501234B1
(en)
|
2009-11-20 |
2017-09-13 |
Tonix Pharma Holdings Limited |
Methods and compositions for treating symptoms associated with post-traumatic stress disorder using cyclobenzaprine
|
|
US20110319389A1
(en)
|
2010-06-24 |
2011-12-29 |
Tonix Pharmaceuticals, Inc. |
Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine
|
|
DK2611440T3
(en)
|
2010-09-01 |
2017-05-15 |
Tonix Pharmaceuticals Inc |
Treatment for cocaine addiction
|
|
US11998516B2
(en)
|
2011-03-07 |
2024-06-04 |
Tonix Pharma Holdings Limited |
Methods and compositions for treating depression using cyclobenzaprine
|
|
ITMI20110558A1
(it)
|
2011-04-06 |
2012-10-07 |
Campiglio Consulting Srl |
Composizione farmaceutica contenente ciclobenzaprina adatta alla somministrazione endonasale
|
|
MX2021005317A
(es)
|
2012-06-15 |
2022-12-16 |
Tonix Pharmaceuticals Inc |
Composiciones y métodos para absorción transmucosa.
|
|
AU2013337742B2
(en)
|
2012-11-05 |
2017-11-23 |
Emory University |
7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
|
|
HUE047547T2
(hu)
|
2013-03-15 |
2020-04-28 |
Tonix Pharma Holdings Ltd |
Ciklobenzaprin-hidroklorid és mannit eutektikus formulációi
|
|
US20160015818A1
(en)
|
2014-07-18 |
2016-01-21 |
Medipath, Inc. |
Compositions and methods for physiological delivery using cannabidiol
|
|
US10357465B2
(en)
|
2014-09-18 |
2019-07-23 |
Tonix Pharma Holdings Limited |
Eutectic formulations of cyclobenzaprine hydrochloride
|
|
MX2020006140A
(es)
|
2017-12-11 |
2020-08-13 |
Tonix Pharma Holdings Ltd |
Tratamiento con ciclobenzaprina para la agitacion, psicosis y deterioro cognitivo en la demencia y enfermedades neurodegenerativas.
|
|
WO2023250036A1
(en)
|
2022-06-21 |
2023-12-28 |
Tonix Pharmaceuticals Holding Corp. |
Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc)
|
